ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as Cystic Fibrosis, Leber's Congenital Amaurosis Type 10, and Dystrophic Epidermolysis Bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, and QRX-323.